{
    "clinical_study": {
        "@rank": "6702", 
        "arm_group": {
            "arm_group_label": "Colesevelam", 
            "arm_group_type": "Other", 
            "description": "1875 mg of Colesevelam orally twice daily for 10 days"
        }, 
        "brief_summary": {
            "textblock": "The investigators' hypothesis is that therapy with Colesevelam, reduces fecal bile acid\n      excretion in patients with IBS-diarrhea with prior evidence of increased fecal 48 hour total\n      bile acid excretion.  The investigators aim to study the ability of the HPLC assay for fecal\n      bile acids to demonstrate responsiveness after treatment with Colesevelam."
        }, 
        "brief_title": "Ability of Mayo Clinic HPLC Method to Measure Fecal Bile Acids", 
        "condition": "Diarrhea Predominant Irritable Bowel Syndrome", 
        "condition_browse": {
            "mesh_term": [
                "Diarrhea", 
                "Irritable Bowel Syndrome"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Patients with IBS-diarrhea with prior evidence of increased fecal 48 hour total bile acid\n        and increased fasting serum 7alphaC4 who meet the following:\n\n        INCLUSION CRITERIA\n\n          -  BDQ- IBS symptoms: Positive by Rome lll criteria\n\n          -  HAD: No restrictions on Hospital Anxiety/Depression score.\n\n          -  Age: 18-65 years\n\n          -  Gender: Men or women.  Women of childbearing potential will have a negative pregnancy\n             test before initiation of medication.\n\n        EXCLUSION CRITERIA\n\n          -  Use of drugs or agents within the past 1 week or planned use in the subsequent 2\n             weeks during the study period (Birth control pill, estrogen replacement therapy, and\n             thyroxine replacement are permissible exceptions):\n\n               -  Agents that alter GI transit including opioids, narcotics, anticholinergics,\n                  tricyclic antidepressants, SNRI antidepressants.\n\n               -  Analgesic drugs including opiates, NSAID, COX 2 inhibitors\n\n               -  Intake of medication that could interfere with the interpretation of the study.\n\n          -  Female subjects who are pregnant or breast-feeding. Females must be either surgically\n             sterilized, postmenopausal (>12 months since last menses), or, if of childbearing\n             potential, using reliable methods of contraception as determined by the physician.\n\n          -  Abdominal surgery (except Appendectomy)\n\n          -  Patients with known chronic liver disease or history of elevated AST/ALT 2.0 X upper\n             limit of normal.\n\n               -  BA synthesis and possible false positive or negative fecal bile acid or serum\n                  7alphaC4 result.  If there is no AST or ALT values in the medical record, the\n                  study physicians will determine if the tests need to be run."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "12", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 9, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02111603", 
            "org_study_id": "14-000384"
        }, 
        "intervention": {
            "arm_group_label": "Colesevelam", 
            "intervention_name": "Colesevelam", 
            "intervention_type": "Drug", 
            "other_name": "Welchol"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Bile Acids and Salts", 
                "Colesevelam"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "April 10, 2014", 
        "location": {
            "contact": {
                "last_name": "Irene A Busciglio, BS", 
                "phone": "507-266-6615"
            }, 
            "facility": {
                "address": {
                    "city": "Rochester", 
                    "country": "United States", 
                    "state": "Minnesota", 
                    "zip": "55905"
                }, 
                "name": "Mayo Clinic in Rochester"
            }, 
            "investigator": [
                {
                    "last_name": "Michael Camilleri, MD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Andres J Acosta Cardenas, MD, PhD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Ability of Mayo Clinic HPLC Method to Measure Fecal Bile Acids to Demonstrate Response to Colesevelam in Patients With Diarrhea Predominant Irritable Bowel Syndrome", 
        "overall_official": {
            "affiliation": "Mayo Clinic", 
            "last_name": "Michael Camilleri, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "We aim to study the ability of the HPLC assay for fecal bile acids to demonstrate responsiveness after treatment with colesevelam.", 
            "measure": "Ability to measure change in fecal bile acids from baseline in response to treatment with colesevelam.", 
            "safety_issue": "No", 
            "time_frame": "10 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02111603"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Mayo Clinic", 
            "investigator_full_name": "Michael Camilleri", 
            "investigator_title": "MD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Change in fasting serum C4 from baseline in response to treatment with colesevelam.", 
                "measure": "Change in fasting serum C4", 
                "safety_issue": "No", 
                "time_frame": "10 days"
            }, 
            {
                "description": "Change in fecal fat excretion from baseline in response to treatment with colesevelam", 
                "measure": "Change in fecal fat excretion", 
                "safety_issue": "No", 
                "time_frame": "10 days"
            }, 
            {
                "description": "Change in stool consistency from baseline in response to treatment with colesevelam.", 
                "measure": "Change in stool consistency", 
                "safety_issue": "No", 
                "time_frame": "10 days"
            }, 
            {
                "description": "Change in stool frequency from baseline in response to treatment with colesevelam.", 
                "measure": "Change in stool frequency", 
                "safety_issue": "No", 
                "time_frame": "10 days"
            }, 
            {
                "description": "Relative composition of the main individual bile acids (CA, CDCA, DCA, LCA and UDCA) in 48 hour stool collection on colesevelam compared to baseline", 
                "measure": "Relative composition of the main individual bile acids", 
                "safety_issue": "No", 
                "time_frame": "10 days"
            }
        ], 
        "source": "Mayo Clinic", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Mayo Clinic", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}